Category - Developments

Developments

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

111, Inc. (NASDAQ:YI) was selected as one of the 2021 Top 20 Internet Healthcare Enterprises in China for its innovation and promotion in the internet+healthcare field and its transformative platform serving the...

October 15, 2021

Developments

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

VistaGen Therapeutics (NASDAQ:VTGN) initiated a Phase 2a clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of anxiety in adults with adjustment disorder with anxiety...

October 14, 2021

Developments

FDA accepts Altamira 510(k) application for Bentrio

Altamira Therapeutics’ (NASDAQ:CYTO) 510(k) application for premarket clearance for its Bentrio nasal spray for protection against airborne allergens was accepted for review by the FDA. The application now moves to a...

October 14, 2021

Developments

Labster to acquire UbiSim in virtual reality training expansion

Labster, a leading platform for virtual labs and interactive science based in Denmark, signed a definitive agreement to acquire UbiSim, a virtual reality training platform for nursing, in a move to further transform...

October 14, 2021

Developments

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...

October 12, 2021

Developments

Titan Pharma, MUSC Foundation in research, option license agreement

Titan Pharmaceuticals (NASDAQ:TTNP) entered into a research and option license agreement with the MUSC Foundation for Research Development (MUSC FRD) and will conduct certain research, evaluation, proof-of-concept...

October 12, 2021

Developments

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Supernus Pharmaceuticals (NASDAQ:SUPN) agreed to acquire Adamas Pharmaceuticals (NASDAQ:ADMS) in a tender offer for $8.10 a share in cash, or about $400-million plus two non-tradable contingent value rights (CVR). The...

October 11, 2021

Developments

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

Hirosaki University Hospital agreed to lease and utilize a Senhance Surgical System from Asensus Surgical (NYSE American: ASXC), which is digitizing the interface between surgeon and patient to enhance performance...

October 6, 2021

Developments

IntelGenx cleared to graduate to Toronto Stock Exchange

IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange. The company’s common stock; 8% convertible debentures, with a maturity date...

October 5, 2021

Developments

VistaGen reports new mechanism of action data for PH94B

VistaGen Therapeutics (NASDAQ:VTGN) announced new mechanism of action data from a preclinical tissue distribution study in laboratory rats demonstrating that a single intranasal administration of radiolabeled carbon-14...

October 5, 2021

Category - Developments

111, Inc. selected to 2021 China Top 20 Internet Healthcare Companies list

VistaGen expands PH948 in Phase 2a trial for adjustment disorder

FDA accepts Altamira 510(k) application for Bentrio

Labster to acquire UbiSim in virtual reality training expansion

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

Titan Pharma, MUSC Foundation in research, option license agreement

Supernus Pharma to acquire Adamas Pharma for $400-million plus CVRs

Hirosaki University Hospital to initiate Asensus Senhance Robotic Surgery program

IntelGenx cleared to graduate to Toronto Stock Exchange

VistaGen reports new mechanism of action data for PH94B

General

More